Explore the Synergy of Combination TKI Therapy
Maneno muhimu
Kikemikali
Maelezo
If the subjects qualify to take part in this research study, they will undergo the following procedures.
Subjects will be asked to abstain from alcoholic beverages (24 hours), grapefruit products, herbal supplements/teas, and over-the-counter medications (48 hours) prior to the study visits. There will be two study periods in this study. During each period all the subjects are outpatients and there will be no overnight stay. During each study period, the subjects will come to the University of Florida Clinical Research Center (UF CRC) three times: on Day -1, Day 1, and Day 2, respectively. Subjects will report to the UF CRC the day before Day 1 (i.e. Day -1) to have clinical lab test and urine pregnancy test (female only). Subjects will come to UF CRC at 6:30 a.m. on Day 1 and Day 2 of each study visit. During the morning of each study period (around 8:30 am) subjects will be randomly assigned to receive a single oral dose of dasatinib 20 mg either with or without a single oral dose of imatinib 400 mg administered one hour prior to dasatinib. After the first study visit, the subjects will return one to two weeks later for the second study visit, receiving the opposite treatment. The treatment order for the study visits will be assigned randomly. The end point measures for this study are plasma concentrations of dasatinib. A total of twelve (12) blood samples will be collected for a total amount of 84 ml (about 3 ounces or about 6 tablespoonsful) for each subject during each study period.
Tarehe
Imethibitishwa Mwisho: | 09/30/2014 |
Iliyowasilishwa Kwanza: | 04/29/2014 |
Uandikishaji uliokadiriwa Uliwasilishwa: | 04/29/2014 |
Iliyotumwa Kwanza: | 05/01/2014 |
Sasisho la Mwisho Liliwasilishwa: | 10/02/2014 |
Sasisho la Mwisho Lilichapishwa: | 10/05/2014 |
Tarehe halisi ya kuanza kwa masomo: | 08/31/2014 |
Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 09/30/2014 |
Tarehe ya Kukamilisha Utafiti: | 09/30/2014 |
Hali au ugonjwa
Uingiliaji / matibabu
Drug: Dasatinib
Drug: Dasatinib+Imatinib
Awamu
Vikundi vya Arm
Mkono | Uingiliaji / matibabu |
---|---|
Placebo Comparator: Dasatinib In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose | Drug: Dasatinib In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose |
Active Comparator: Dasatinib+Imatinib In this group, subjects will take imatinib prior to dasatinib administration.
Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose | Drug: Dasatinib+Imatinib In this group, subjects will take imatinib prior to dasatinib administration.
Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose |
Vigezo vya Kustahiki
Zama zinazostahiki Kujifunza | 18 Years Kwa 18 Years |
Jinsia Inastahiki Kujifunza | All |
Hupokea Wajitolea wa Afya | Ndio |
Vigezo | Inclusion Criteria: - under healthy condition - Non-smokers (self-reported) age 18 -55 years - Body Mass Index (BMI) between 18 to 30 kg/m2 inclusive - Signed Informed Consent Exclusion Criteria: - Any evidence of renal dysfunction (estimated creatinine clearance < 80ml/min). - Any evidence of impaired hepatic function (liver enzymes greater than two times the upper limit of normal or total bilirubin > 2.0 mg/dL). - Taking any medications other than oral contraceptives or hormonal replacement therapy. - Use of any known inhibitor or inducer of CYP3A or P-gp within 30 days prior to study drug administration. - Consumption of alcohol, grapefruit, star fruit, grapefruit products or star fruit products within the 72-hour period prior to study drug administration. - Women who are pregnant or currently breastfeeding. - Donation or loss of 550 mL or more blood volume (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to initial study drug administration. - Known adverse effect or intolerance to imatinib or dasatinib. |
Matokeo
Hatua za Matokeo ya Msingi
1. Area under the plasma concentration versus time curve (AUC) of dasatinib [0, 0.5, 1, 1.5, 2, 3, 4, 6, 9, 12, 15, and 24 hours post-dose]